Loading...

Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_Purified_053107
Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
  • OKT3_Purified_053107
    Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317301 25 µg 30 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317302 100 µg 55 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  2. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  3. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  4. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  5. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  6. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  7. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  8. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  9. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  10. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  11. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  12. Hawley KM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2209044119. PubMed
  13. Sun X, et al. 2023. Cell Death Dis. 14:242. PubMed
  14. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  15. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  16. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  17. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  18. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  19. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  20. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  21. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  22. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  23. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  24. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  25. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  26. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  27. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  28. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  29. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  30. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  31. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  32. Willimsky G, et al. 2021. Elife. 10:. PubMed
  33. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  34. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  35. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  36. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  37. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  38. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  39. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  40. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  41. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  42. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  43. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  44. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  45. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  46. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  47. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  48. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  49. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  50. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  51. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  52. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  53. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  54. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  55. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  56. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  57. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  58. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  59. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  60. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  61. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  62. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  63. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  64. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  65. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  66. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  67. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  68. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  69. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  70. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  71. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  72. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  73. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  74. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  75. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  76. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  77. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  78. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  79. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  80. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  81. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  82. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  83. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  84. Henrick BM, et al. 2021. Cell. . PubMed
  85. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  86. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  87. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  88. Ardain A, et al. 2019. Nature. 570:528. PubMed
  89. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  90. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  91. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  92. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  93. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  94. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  95. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  96. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  97. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  98. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  99. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  100. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  101. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  102. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  103. Naranbhai V, et al. 2022. Cell. . PubMed
  104. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  105. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  106. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  107. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  108. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  109. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  110. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  111. He Y, et al. 2021. eLife. 10:00. PubMed
  112. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  113. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  114. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  115. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  116. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  117. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  118. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  119. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  120. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
RRID
AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD3
Specificity Alt (DOES NOT SHOW ON TDS):
CD3
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IHC-F
UniProt
View information about CD3 on UniProt.org
Go To Top Version: 2    Revision Date: 06.12.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account